Swiss Nordic Bio

As the EU pushes for a more competitive life science sector, Medicon Valley Alliance is reaching across borders to connect Europe's fragmented innovation clusters rather than let each country try to build everything alone.

Nanexa has entered into a global exclusive license and collaboration agreement with Novo for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

The Helsinki-based company has closed a EUR 30 million Series A round led by Hadean Ventures to take its lead candidate, a TrkB potentiator designed to deliver the benefits of psychedelics without the hallucinations, into clinical trials for major depressive disorder.

The Oslo-based radiopharmaceutical company has raised NOK 148.5 million in a private placement and retail offering to complete its Phase 2 ovarian cancer trial and prepare for Phase 3.

As HealthCap marks 30 years of life science investing, co-founder Björn Odlander reflects on the firm’s long-term approach, the journey from lab to patient, and Europe’s widening capital gap.

Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.

Patients who had high-risk polyps removed and waited five years for their first follow-up colonoscopy had a colorectal cancer risk similar to those examined after three years, according to two studies in the New England Journal of Medicine involving Karolinska Institutet (KI) researchers.